Shares of Viking Therapeutics ... boosted its stock after positive trial results since the start of this year, and analysts say it might happen again. In the long term, analysts predict that ...

Viking Therapeutics has faced a tough start to 2025 ... In a recent Stocktwits poll, retail traders were asked for their ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound ...

Taking a breather after a stellar year. Viking Therapeutics stock is up more than 283% from its 2015 initial public offering (IPO) share price. It is about 68% lower than its all-time high.

Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects. This year ...

Viking Therapeutics VKTX is set to report third ... Our proven model does not predict an earnings beat for Viking this time around. The combination of a positive Earnings ESP and a Zacks Rank ...

Viking Therapeutics may be on the verge of a breakthrough ... The Motley Fool has a disclosure policy. Pfizer Stock Analysis: Buy, Sell, or Hold? Don't Fall for These 3 Dividend Stocks: They ...

Demand for these products surpasses supply, and analysts predict that sales growth for ... Unlike Eli Lilly and Novo Nordisk, Viking is a clinical-stage company. It doesn't have any products ...

In the long term, analysts predict that Viking's anticipated oral weight-loss drug could claim about 10% of the market in the years following its projected 2030 release. Viking Therapeutics (VKTX ...

For example, last year, when Viking first announced phase 2 results from the subcutaneous VK2735, the stock soared in the ... What does this mean for investors? I predict Pfizer's danuglipron ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them.